Samantha M. Golomb

TL;DR: This study demonstrates a translational framework for treating rapidly evolving tumors through preclinical modeling and single-cell analyses and demonstrates that combination of IMC-targeting tyrosine kinase inhibitor cabozantinib and immune checkpoint blockade enhances anti-tumor immunity, and overcomes resistance.

TL;DR: The results demonstrate that loss of Cx3cr1 in CNS-myeloid triggers a Cxcl10-mediated vicious cycle, cultivating a br-met-promoting, immune-suppressive niche.

TL;DR: Systemic changes due to aging and gut Dysbiosis increase propensity for neuroinflammation, providing insights into gut dysbiosis in age-related neurological diseases.

TL;DR: Guldner et al. as discussed by the authors described a protocol for epitope and RNA-preserving dissociation of adult mouse brains and subsequent leukocyte purification and staining, which is adaptable to homeostatic and pathogenic brains.

TL;DR: In this paper, a combinatorial immunotherapy of IMC-targeting tyrosine kinase inhibitor cabozantinib and immune checkpoint blockades was proposed to combat acquired resistance to targeted cancer therapy.